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Background: Hash oil, a cannabis preparation that contains ultra-high concentrations of 
tetrahydrocannabinol (THC), is quickly gaining popularity in the United States. Some 
evidence suggests that hash oil might produce greater intoxication and more severe 
negative effects than marijuana. This study examined whether the subjective effects of 
hash oil are more extreme than the subjective effects of marijuana and whether frequency 
of hash oil use is associated with the subjective effects of marijuana and hash oil. 
Method: Past-year cannabis users (n = 1,268) were recruited online to complete a 
questionnaire about the subjective effects of cannabis. Participants who reported past-
year use of both hash oil and marijuana (n = 574) rated subjective effects of each type of 
cannabis in the following positive and negative domains: positive affect, cognitive 
enhancement, negative affect, cognitive impairment, physiological effects, reduced 
consciousness, and psychotic-like experiences. Results: Results of within-person 
comparisons showed that hash oil was rated as producing lesser positive effects (Hash 
oil: M = 4.53, Marijuana: M = 5.55, t = 14.67, p < .001) than marijuana. Negative effects 
of hash oil were minimal for the full sample (n = 574) and for both frequent and 
infrequent hash oil users. In general, the frequency of hash oil use was not associated 
with the subjective effects of marijuana but more frequent hash oil use was associated 
with rating hash oil as producing greater positive effects ( = 0.28, t = 6.86, p < .001) and 
lesser negative effects ( = -0.16, t = -3.83, p < .001). Findings were unchanged after 
controlling for sex, medical cannabis use, and frequency of marijuana use. 
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Conclusions: Hash oil produced lesser positive effects than marijuana. Negative effects of 
hash oil were minimal, suggesting that extreme negative effects may be unlikely for 
experienced cannabis users.  
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 As of 2019, more than half of U.S. states have legalized cannabis for either 
medical or recreational purposes. Concomitantly, prevalence rates of cannabis use have 
increased, with estimates showing that nearly 14% of adults aged 18+ reported cannabis 
use in 2014 (Carliner et al., 2017). Studies show that the perceived risk of cannabis use is 
declining (Smart, Caulkins, Kilmer, Davenport, & Midgette, 2017; Miech et al., 2018), 
but there is speculation that the actual risk of cannabis use may be increasing due to 
increased cannabis potency (ElSohly et al., 2016; Loflin & Earleywine, 2014; Meier, 
2017). Cannabis potency, which is typically judged by the concentration of delta-9-
tetrahydrocannabinol (THC; the main psychoactive constituent of cannabis), has 
increased dramatically from 1995 to 2014 (ElSohly et al., 2016). The increase in cannabis 
potency is concerning because higher-potency cannabis might cause more severe acute 
negative or impairing effects, such as psychotic-like experiences, cognitive impairment, 
and loss of consciousness (Cavazos-Rehg et al., 2016; Chan et al., 2017; Di Forti et al., 
2009; D’Souza et al., 2004; Freeman & Winstock, 2015; Quinn, Wilson, Cockshaw, 
Barkus, & Hides, 2017). Moreover, higher-potency cannabis might result in stronger 
positive or reinforcing acute effects, such as liking of the drug effect (Chait & Burke, 
1994; Freeman & Winstock, 2015), or increased tolerance and withdrawal, all of which 
drive continued use and increase risk for cannabis use disorder (Freeman & Winstock, 
2015; Loflin & Earleywine, 2014; Meier 2017; Pang, Guillot, Zvolensky, Bonn-Miller, & 
Leventhal, 2017). However, there is little research on the effects of increased cannabis 
potency on acute responses to cannabis.  
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Insight into the potentially stronger positive and negative acute effects produced 
by higher potency cannabis can be gleaned from cannabis administration studies. 
Numerous studies have administered cannabis with different THC concentrations (e.g., 
0.63% vs. 1.95%; Chait & Burke, 1994) to the same people at different times using a 
standardized smoking procedure (e.g., by controlling number of puffs, puff duration, 
etc.). Most of these studies have shown that higher potency cannabis produces greater 
euphoria and stronger physiological effects (Chait & Burke, 1994; Hunault et al., 2008; 
Hunault et al., 2009). For example, one study found that, compared with lower potency 
cannabis (0.63% THC), higher potency cannabis (1.95% THC) resulted in higher ratings 
of liking the drug effect and greater increases in heart rate (Chait & Burke, 1994). Some 
studies also found that higher potency cannabis produced more severe psychotic-like 
experiences (e.g., altered perception), negative affect (e.g., anxiety), and cognitive 
impairment (D’Souza et al., 2004; Hunault et al., 2014), which are generally not 
associated with decreased likelihood of continued use (Pang et al., 2017).  
However, the external validity of cannabis administration studies is limited. For 
example, cannabis administered in the lab typically has much lower concentrations of 
THC than cannabis available in the real world (Stith & Vigil, 2016; Vergara et al., 2017). 
This is because, in the United States, cannabis for research purposes must come from the 
National Institute on Drug Abuse (NIDA), and cannabis provided by NIDA for cannabis 
administration studies has, on average, 5.15% THC, which is only 27% of current THC 
concentrations in recreational markets (e.g., 19.04% THC in Seattle, Washington; 
Vergara et al., 2017). Only one cannabis administration study compared the acute effects 
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of cannabis with as high as 23.12% THC to cannabis with no THC (.003% THC), low 
THC (9.75%), and moderate THC (a 50/50 mix between the 9.75% THC cannabis and 
the 23.12% THC cannabis) (Hunault et al., 2014). That study found that ratings of liking 
were highest for the lower-potency cannabis (i.e., 9.75% THC) compared with the no 
THC cannabis and the moderate- and high-potency cannabis. Moreover, the highest-
potency cannabis produced greater negative affect (e.g., feeling down), stronger 
physiological effects (e.g., dizziness), and self-reported impaired memory (Hunault et al., 
2014). These findings are consistent with research suggesting that the reinforcing effects 
of THC  follow an inverted-U-shaped curve such that very low- and very high-potency 
cannabis are less desirable than medium-potency cannabis (Curran et al., 2016; Hunault 
et al., 2014; Sanudo-Pena et al., 1997), possibly because the negative effects of high 
doses of THC counteract any positive effects (Curran et al., 2016; Zernig, Wakonigg, 
Madlung, Haring, & Saria, 2004; Figure 1).  
 A complementary approach to cannabis administration studies, which have strong 
internal validity but limited external validity, is observational research comparing 
reported effects of different cannabis preparations known to vary greatly in average THC 
content. Two main cannabis preparations that differ in average THC content are 
marijuana and hash oil. Marijuana (i.e., flower) refers to the dried buds of the cannabis 
plant and contains, on average, 12 -20% THC (DEA, 2017; ElSohly et al., 2016; Smart et 
al., 2017; Vergara et al., 2017). Hash oil refers to a highly concentrated extract of 
cannabis plant material, and contains, on average, 54% THC, but can exceed 80% THC 
(DEA, 2017; ElSohly et al., 2016; Raber, Elzinga, & Kaplan, 2015; Smart et al., 2017; 
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Stogner & Miller, 2015). Hash oil is extracted from cannabis plant material using a 
solvent, such as butane or supercritical carbon dioxide. Hash oil is colloquially referred to 
as “concentrates” or butane hash oil (BHO), dab, wax, shatter, budder, crumble, or honey 
oil.  
Several observational studies have reported on the acute effects of hash oil. For 
example, one study collected one month of Twitter data to examine extreme effects of 
hash oil by randomly selecting 3,540 out of 206,854 tweets containing at least one hash 
oil-related keyword (e.g., dab, wax, shatter, honey oil, concentrate; Cavazos-Rehg et al., 
2016). Twenty-two percent of hash oil-related tweets mentioned extreme effects, which 
were coded as physiological effects (e.g., passing out/losing consciousness; 
nausea/vomiting; loss of bodily control), cognitive/psychological effects (e.g., confusion 
or distorted reality; memory loss), and general (non-specific) effects (e.g., “Took my first 
dab Tuesday. Almost died.”). Of the 22% of hash oil-related tweets mentioning extreme 
effects, most effects were classified as general effects (non-specific) (46%), 37% were 
classified as physiological effects, and 17% were classified as cognitive/psychological 
effects. Thus, when specific extreme effects were reported, most were physiological 
effects, as opposed to cognitive or psychological effects. However, in a subsequent study 
of 232 cannabis users aged 18-35 recruited online, almost 36% of participants who used 
hash oil reported extreme effects, with altered reality/confusion being the most 
commonly reported extreme effect (23.3%), followed by rapid heartbeat (11.2%), lung 
pain (9.9%), severe paranoia (6.9%), loss of bodily control (5.2%), and passing out/losing 
consciousness (3.5%; Cavazos-Rehg, 2018). Thus, these studies suggest that at least 
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some hash oil users experience extreme negative effects across psychological and 
physiological domains. However, it is not clear from these studies if effects of hash oil 
are more extreme than marijuana or if extreme effects of hash oil are more common than 
extreme effects of marijuana. Thus, a direct comparison of hash oil with marijuana would 
provide further insight into cannabis potency effects. 
We are aware of only one observational study that conducted a within-person 
comparison of the effects of marijuana and hash oil (Chan et al., 2017). That study was 
an online survey of 181,870 participants aged 18+ recruited internationally as part of the 
Global Drug Survey. Analyses compared ratings of the effects of marijuana and butane 
hash oil (BHO) in 5,676 participants who reported past-year use of both marijuana and 
BHO. The study, which examined a limited number of effects, found that cannabis users 
generally reported that BHO caused greater negative effects than marijuana, including 
reduced ability to function and greater preoccupation/distraction, forgetfulness, 
restlessness/anxiety, racing thoughts, and hangover effects. Cannabis users also rated 
hash oil as producing fewer overall pleasurable effects than marijuana. However, if hash 
oil effects are less positive than marijuana, as suggested by the Global Drug Survey 
(Chan et al. 2017) and by the inverted U-shaped dose-effect curve (Curran et al., 2016; 
Hunault et al. 2009), and hash oil effects are more negative than marijuana (Chan et al., 
2017; Hunault et al., 2014), it is unclear why people are using hash oil (Carlini, Garrett, 
& Harwich, 2017; Meacham, Paul, & Ramo, 2018; Smart et al., 2017).  
One possibility is that the extent to which marijuana is rated as producing greater 
positive and lesser negative effects than hash oil differs as a function of previous hash oil 
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exposure (Hall, 2009). In this case, more frequent hash oil users, who are exposed to the 
much higher concentrations of THC in hash oil, might have developed greater tolerance 
to THC than less frequent hash oil users. Drug tolerance could result in a lateral, 
rightward shift in the inverted U-shaped reward-aversion dose-effect curve. This lateral 
shift in the inverted U-shaped curve yields two main predictions. First, cannabis users 
with greater tolerance to THC (frequent hash oil users) will experience less pronounced 
positive and negative subjective effects of lower-THC cannabis (i.e., marijuana) than 
cannabis users with lower tolerance to THC (infrequent hash oil users). Second, cannabis 
users with greater tolerance to THC (frequent hash oil users) will experience more 
positive and less negative subjective effects of high-THC cannabis (i.e., hash oil) than 
cannabis users with lower tolerance to THC (infrequent hash oil users), as the negative 
effects of the higher doses of THC in hash oil might counteract positive effects for 
cannabis users with lower tolerance to THC (Figure 2; Curran et al., 2016; Zernig et al., 
2004). Thus, previous hash oil exposure could result in the profile of subjective effects of 
marijuana versus hash oil looking different for frequent and infrequent hash oil users. In 
support of these predictions, evidence suggests that subjective cannabis effects are less 
pronounced for regular users (users with high tolerance to THC) than for occasional users 
(users with lower tolerance to THC) (Colizzi & Bhattacharya, 2018). 
The present study had three aims. First, we tested whether the positive and 
negative subjective effects of cannabis differed for marijuana and hash oil. To test this 
aim, we conducted within-person comparisons of the self-reported subjective effects of 
marijuana and hash oil. Within-person comparisons are important because they control 
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for the effects of background factors, such as sex, race, and genetics, on subjective 
response. We hypothesized that individuals who used both marijuana and hash oil would 
rate marijuana as producing greater positive effects  and lesser negative effects than hash 
oil, consistent with the one previous study that conducted within-person comparisons of 
the subjective effects of marijuana and hash oil (Chan et al., 2017) and consistent with 
the inverted U-shape reward-aversion dose-effect curve (i.e., medium doses of THC are 
preferred to high and low doses) (Curran et al., 2016; Hunault et al. 2009). Second, we 
tested whether the subjective effects of marijuana, and subsequently, the subjective 
effects of hash oil, differed as a function of frequency of hash oil use. We hypothesized 
that more frequent hash oil users would have higher tolerance to THC than less frequent 
hash oil users and would, therefore, rate marijuana as producing lesser positive effects 
and lesser negative effects as compared with less frequent hash oil users and would rate 
hash oil as producing greater positive and lesser negative effects as compared with less 
frequent hash oil users (Figure 3). Third, we tested whether the relative difference in 
subjective response to marijuana versus hash oil would differ for more versus less 
frequent hash oil users. In terms of positive effects, we hypothesized that the relative 
difference in effects for marijuana versus hash oil would favor marijuana for infrequent 
hash oil users (i.e., infrequent hash oil users would rate marijuana more positively than 
hash oil) and would favor hash oil for frequent hash oil users (i.e., frequent hash oil users 
would rate hash oil more positively than marijuana). In terms of negative effects, we 
hypothesized that both frequent and infrequent hash oil users would rate hash oil as 
producing greater negative effects relative to marijuana but the negative effects of hash 
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oil relative to marijuana would be more extreme for infrequent hash oil users compared 
with frequent hash oil users.  
This research builds on the single extant study (i.e., Chan et al., 2017) on the 
subjective effects of marijuana and hash oil by considering a wider range of subjective 
effects, and by examining how frequency of hash oil use is associated with subjective 
effects of marijuana and hash oil. We consider subjective cannabis effects in a number of 
positive and negative effect domains, including positive affect, cognitive enhancement, 
negative affect, psychotic-like experiences, cognitive impairment, physiological effects, 
and reduced consciousness. These domains were chosen based on cannabis 
administration studies and observational studies that have suggested that cannabis acutely 
affects these domains (Cavazos-Rehg et al., 2016; Chait & Burke, 1994; D’Souza et al., 
2004; Hunault et al., 2014; Quinn et al., 2017).  
METHOD 
Participants  
Adult cannabis users were recruited to participate in an anonymous, online survey 
through various social media outlets (i.e., Reddit, Facebook, Craigslist, Bluelight). 
Recruitment posts targeted cannabis users through forums and groups focused on 
recreational and medical cannabis. Eligible participants were past-year cannabis users 
aged 18 years and older residing in the United States. All participants provided informed 
consent and were notified that responses for each question were both voluntary and 
anonymous. Participants who completed the survey were given the option of being 
entered into a drawing to win one of two $200 Amazon gift cards or one of four $50 
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Amazon gift cards. To ensure anonymity of survey responses, participants entered the 
raffle through a separate questionnaire upon survey completion. Precautions were taken 
to prevent ballot stuffing and ensure one response per participant. A total of 1,249 
participants completed the survey. To compare within-person effects of marijuana and 
hash oil, analyses were limited to the 605 participants (48.44%) who reported past use of 
both marijuana and hash oil use. Of the 605 participants who reported past use of 
marijuana and hash oil, n = 31 (5.12%) were excluded due to being flagged for invalid 
responses (< 75% accuracy on 11 validity questions; Supplemental Table 1). Of the 574 
remaining participants, the majority were male (n = 318; 55.40%) and Caucasian 
(Caucasian [n = 428, 74.56%], Hispanic [n = 63, 10.98%], Asian or Pacific Islander [n = 
29, 5.05%], African American [n = 17, 2.96%], American Indian or Alaska Native [n = 
14, 2.44%], and Other [n = 23, 4.01%]). The mean age of participants was 32.21 (SD = 
12.62). This study was approved by the University’s Institutional Review Board.  
Measures  
 Cannabis use. Participants were asked questions about their average frequency of 
both marijuana and butane hash oil use. Butane hash oil was specifically queried because 
it is the most popular form of hash oil and because it allows for a direct comparison to the 
previous study comparing subjective effects of marijuana and hash oil (Chan et al., 2017). 
Questions were taken from the Daily Sessions, Frequency, Age of Onset, and Quantity of 
Cannabis Use Scale (DFAQ-CU), which has previously been shown to be reliable and 
valid (Cuttler & Spradlin, 2017). The DFAQ-CU was adapted to ask about each type of 
cannabis separately (i.e., marijuana and hash oil). To ensure that participants only 
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reported on marijuana, and subsequently, only reported on hash oil, questions were 
prefaced with directions to report only on the one form of cannabis (marijuana or hash 
oil) and written directions were accompanied by images of each type of cannabis (Figure 
4). Participants were asked “Which of the following best captures the average frequency 
you currently use [marijuana, butane hash oil]?” Response options ranged from 1 (less 
than once a year) to 12 (more than once a day). Participants were then asked, “Which of 
the following best captures how long you have been using [marijuana, butane hash oil] at 
this frequency?” Response items ranged from 1 (less than one month) to 12 (more than 
20 years). 
Subjective cannabis effects. Subjective cannabis effects were asked separately 
for marijuana and hash oil, with directions to report only on marijuana and, subsequently, 
to report only on hash oil. To ensure accurate reporting, questions were accompanied by 
pictures of each form of cannabis (Figure 4). Questions about subjective cannabis effects 
were taken from several different sources, including the Global Drug Survey (Chan et al., 
2017), the Twitter study of hash oil effects (Cavazos-Rehg et al., 2016), the Cannabis 
Experiences Questionnaire – Intoxication Effects Checklist (CEQ-I; Quinn et al., 2017), 
and previous visual analog scales used in cannabis administration studies (e.g., Hunault et 
al., 2014). When items from different studies overlapped substantially or were identical 
(e.g., ‘Anxious’ from Quinn et al., 2017 and ‘Anxious’ from Chan et al., 2017), only one 
item was selected for inclusion in the survey. Items were selected with the aim of 
understanding positive and negative effects of both marijuana and hash oil. Positive 
effects were examined in two domains: positive affect and cognitive enhancement. 
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Positive affect was further split into a low arousal (e.g., relaxed) and a high arousal (e.g., 
excited) scale as cannabis research indicates that low arousal cannabis effects are more 
commonly reported than high arousal effects (Zeiger et al., 2010). Negative effects were 
examined in five domains: negative affect, cognitive impairment, psychotic-like 
experiences, physiological effects, and reduced consciousness. As with positive affect, 
negative affect was split into a low arousal (e.g., depressed) and a high arousal (e.g., 
anxious) scale. Response options ranged from 0 to 10 (not at all [0] to extremely [10] or 
never [0] to always [10]). Scale items were averaged to create a total score for each 
subjective effect scale. Table 1 shows items (with sources) used to assess each domain. 
Internal consistency was good for both positive effect domains and negative effect 
domains for marijuana (total positive effects [α = 0.88], positive affect – low arousal [α = 
0.81], positive affect – high arousal [α = 0.74], cognitive enhancement [α = 0.85], total 
negative effects [α = 0.95], negative affect – low arousal [α = 0.83], negative affect – 
high arousal [α = 0.84], psychotic-like experiences [α = 0.86], cognitive impairment [α = 
0.73], physiological effects [α = 0.78], and reduced consciousness [α = 0.78]) and for 
hash oil (total positive effects [α = 0.93], positive affect – low arousal [α = 0.87], positive 
affect – high arousal [α = 0.84], cognitive enhancement [α = 0.91], total negative effects 
[α = 0.96], negative affect – low arousal [α = 0.86], negative affect – high arousal [α = 
0.88], psychotic-like experiences [α = 0.87], cognitive impairment [α = 0.81], 
physiological effects [α = 0.82], and reduced consciousness [α = 0.75]). Participants 
received a total score for each scale if they responded to at least 75% of items in that 
scale. For example, participants received a low arousal positive affect score if they 
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responded to at least three out of four low arousal positive affect scale items. Of the 574 
participants, n = 534 (93.03%) had total scores computed for all 22 subjective effect 
scales (i.e., subjective scales for both marijuana and hash oil including total positive 
effects, low arousal positive affect, high arousal positive affect, cognitive enhancement, 
total negative effects, low arousal negative affect, high arousal negative affect, psychotic-
like experiences, cognitive impairment, physiological effects, and reduced 
consciousness). The remaining 40 participants had total scores computed for at least one 
subjective effect scale with the majority of these remaining participants (n = 31) having 
total scores computed for at least half (i.e., 11 out of 22) of the subjective effect scales. 
Total scores for each domain were log-transformed prior to statistical testing due to the 
skewed distribution of the data.  
Statistical Analyses 
To compare subjective effects of marijuana and hash oil within individuals, we 
used paired t-tests. To test whether the subjective effects of marijuana, and subsequently 
the subjective effects of hash oil, were associated with frequency of current hash oil use, 
we regressed subjective effects of marijuana, and subsequently subjective effects of hash 
oil, on frequency of current hash oil use, controlling for sex, medical cannabis use, and 
current frequency of marijuana use. To test whether relative differences in the subjective 
effects of marijuana versus hash oil were associated with frequency of current hash oil 
use, we computed difference scores representing the difference in each person’s rating of 
the subjective effect of marijuana versus hash oil (e.g., marijuana positive effect scale 
minus hash oil positive effect scale). Then we regressed that difference score on current 
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frequency of hash oil use, controlling for sex, medical cannabis use, and current 
frequency of marijuana use. 
RESULTS 
Sample Characteristics  
Table 2 shows characteristics for the full sample of participants (n = 574) who 
reported use of both marijuana and hash oil. In the full sample, marijuana use was 
frequent, with an average frequency of use of approximately five to six times per week 
(corresponding to M = 10.07, SD = 2.69). Hash oil use was less frequent, with an average 
frequency of use of nearly two to three times per month (corresponding to M = 5.63, SD 
= 3.78). To elucidate the demographic and cannabis use correlates of more frequent hash 
oil use, characteristics are shown for frequent and infrequent hash oil users separately 
(Table 2). Groups were based on a median split. Frequent hash oil users were more likely 
to be male (61.83% frequent hash oil users vs. 50.00% infrequent hash oil users, χ 2 = 
8.39, p = .02) and to have a medical marijuana card (41.98% frequent hash oil users vs. 
25.64% infrequent hash oil users, χ 2 = 17.18, p < .001) than infrequent hash oil users. 
This finding is consistent with some research suggesting that men (Daniulaitye et al., 
2017) and medical cannabis cardholders (Lankenau et al., 2017) are more likely to use 
hash oil than women and cannabis users who do not have a medical cannabis card. The 
two groups (i.e., frequent and infrequent hash oil users) did not differ in terms of 
frequency of marijuana use (frequent hash oil users: M = 10.18, SD = 2.59; infrequent 
hash oil users: M = 9.98, SD = 2.77; t (572) = -0.88, p = .38).  
Within-person Comparison of the Subjective Effects of Marijuana and Hash Oil 
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We conducted within-person comparisons to test whether positive and negative 
subjective effects differed for marijuana and hash oil. We hypothesized that individuals 
who used both marijuana and hash oil would rate marijuana as producing greater positive 
effects and lesser negative effects than hash oil. Results were somewhat consistent with 
hypotheses (Table 3). Consistent with hypotheses, marijuana was rated as producing 
greater total positive effects than hash oil (marijuana positive effects total: M = 5.55, SD 
= 1.70; hash oil positive effects total: M = 4.53, SD = 2.13; paired t = 14.67, p < .001). 
Inconsistent with hypotheses, total negative effects did not differ between marijuana and 
hash oil (marijuana negative effects total: M = 1.37, SD = 1.09; hash oil negative effects 
total: M = 1.41, SD = 1.30; paired t = 1.63, p = 0.10). Notably, however, marijuana was 
rated as producing lesser physiological effects and a lower likelihood of causing reduced 
consciousness than hash oil but greater negative affect (both low and high arousal 
negative affect), psychotic-like experiences, and cognitive impairment relative to hash oil 
(Table 3). However, means for negative effects were quite small, indicating that negative 
effects of both marijuana and hash oil are mild or infrequent. Thus, the main difference 
between marijuana and hash oil, as indicated by effect sizes, was that marijuana produces 
more positive effects than hash oil.  
Subjective Effects of Marijuana and Hash Oil as a Function of Frequency of Hash 
Oil Use  
To ascertain if ratings of the subjective effects of marijuana and hash oil differed 
as a function of frequency of hash oil use, each subjective effect was regressed on 
frequency of hash oil use, and the results of these statistical tests are reported in Table 4. 
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To aid interpretation of statistical tests, we report mean subjective effect ratings for 
frequent and infrequent hash oil users (with groups based on a median split). We 
hypothesized that frequent hash oil users would rate marijuana as producing lesser 
positive and negative effects than infrequent hash oil users. Contrary to hypotheses, 
results showed that frequency of hash oil use was unrelated to the positive effects of 
marijuana ( = -0.00, t = -0.08, p = 0.94). However, consistent with hypotheses, greater 
frequency of hash oil use was associated with marijuana producing lesser total negative 
effects ( = -0.12, t = -2.81, p = 0.01). In general, however, frequency of hash oil use was 
not statistically significantly associated with the negative effect scales, including low 
arousal negative affect, psychotic-like experiences, physiological effects, and reduced 
consciousness. The exceptions were that more frequent hash oil use was associated with 
rating marijuana as producing lesser high arousal negative affect and lesser cognitive 
impairment. After additionally controlling for sex, medical cannabis use, and frequency 
of marijuana use, frequency of hash oil use was only significantly related to rating 
marijuana as having lesser high arousal negative affect. 
We then tested whether the subjective effects of hash oil would differ as a 
function of frequency of hash oil use (Table 4). We hypothesized that frequent hash oil 
users would rate the subjective effects of hash oil as producing greater positive effects 
and lesser negative effects than infrequent hash oil users. Findings supported these 
hypotheses. Analyses revealed that more frequent hash oil use was associated with higher 
ratings of the positive effects of hash oil and lower ratings of the negative effects of hash 
oil. For example, the results of a regression showed that as frequency of hash oil use 
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increased, hash oil was rated as producing greater total positive effects ( = 0.28, t = 
6.86, p = < .001). The means for the total positive effects of hash oil for frequent and 
infrequent users also illustrate this. Frequent hash oil users rated the total positive effects 
of hash oil as higher (M = 5.00, SD = 1.96, range 0 to 10) than infrequent hash oil users 
(M = 4.14, SD = 2.18). These findings were generally unchanged after additionally 
controlling for sex, medical cannabis use, and frequency of marijuana use.   
Within-Person Difference Ratings for Marijuana and Hash Oil as a Function of 
Frequency of Hash Oil Use  
Table 5 shows a test of whether the relative difference in the subjective response 
to marijuana versus hash oil differed as a function of frequency of hash oil use. We first 
computed the difference in ratings for marijuana versus hash oil (e.g., marijuana positive 
effect minus hash oil positive effect). To ascertain if difference scores differed as a 
function of frequency of hash oil use, each subjective effect difference score was 
regressed on frequency of hash oil use. The results of these statistical tests are reported in 
the shaded columns of Table 5. To aid interpretation of statistical tests of the association 
between difference scores and frequency of hash oil use, we report within-person means 
on the subjective effect scales for marijuana and hash oil for both frequent and infrequent 
hash oil users (with groups based on a median split). We hypothesized that frequent hash 
oil users would rate marijuana less positively than hash oil (i.e., the difference score for 
positive effects of marijuana minus hash oil would be negative) and, conversely, that 
infrequent hash oil users would rate marijuana more positively than hash oil (i.e., the 
difference score for positive effects of marijuana minus hash oil would be positive). 
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However, analyses revealed that both frequent and infrequent hash oil users rated 
marijuana as producing greater positive effects than hash oil. Nonetheless, the extent to 
which marijuana was rated as producing greater positive effects was attenuated for 
frequent hash oil users compared with infrequent hash oil users. For example, results of a 
regression analysis showed that more frequent hash oil use was associated with a smaller 
difference in the extent to which marijuana was rated as producing greater total positive 
effects (range 0 to 10) than hash oil ( = -0.37, t = 9.53, p = < .001). The means show this 
pattern clearly. For example, frequent hash oil users rated the difference in total positive 
effects between marijuana and hash oil as less extreme (Marijuana: M = 5.49, Hash oil: M 
= 5.00, Difference [marijuana minus hash oil]: 0.49) than infrequent hash oil users 
(Marijuana: M = 5.61, Hash oil: M = 4.14, Difference [marijuana minus hash oil]: 1.47). 
These findings were generally unchanged after additionally controlling for sex, medical 
cannabis use, and frequency of marijuana use.  
We also hypothesized that both frequent and infrequent hash oil users would rate 
marijuana as producing lesser negative effects than hash oil, but that this difference 
would be attenuated for frequent hash oil users. Results were somewhat consistent with 
this hypothesis. For example, consistent with this hypothesis, both frequent and 
infrequent hash oil users rated marijuana as producing lesser physiological effects than 
hash oil, and the extent to which marijuana was rated as producing lesser physiological 
effects was attenuated for frequent hash oil users. A similar pattern was also observed for 
reduced consciousness. However, contrary to hypotheses, a different pattern of results 
was found for both high arousal negative affect and cognitive impairment. In terms of 
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high arousal negative affect, both frequent and infrequent hash oil users rated marijuana 
as producing higher levels of negative affect than hash oil. Surprisingly, the extent to 
which marijuana was rated as producing greater high arousal negative affect was actually 
more extreme for frequent hash oil users compared with infrequent hash oil users. In 
terms of cognitive impairment, frequent hash oil users rated marijuana as producing more 
cognitive impairment than hash oil and, conversely, less frequent hash oil users rated 
marijuana as producing less cognitive impairment than hash oil. Results were generally 
unchanged after additionally controlling for sex, medical cannabis use, and frequency of 
marijuana use. 
DISCUSSION 
 The purpose of this study was to compare the positive and negative subjective 
effects of two types of cannabis known to vary in average THC content: marijuana and 
hash oil. We hypothesized that lower THC cannabis (i.e., marijuana) would be rated as 
producing greater positive effects and lesser negative effects than higher THC cannabis 
(i.e., hash oil), consistent with research demonstrating that the reinforcing effects of THC 
follow an inverted U-shaped curve whereby medium doses of THC are preferred to high 
and low doses of THC (Curran et al., 2016, Hunault et al., 2014). Findings showed that 
marijuana was rated as producing greater positive effects and lesser physiological effects 
than hash oil, consistent with hypotheses. However, marijuana was also rated as 
producing worse negative affect and cognitive impairment than hash oil. In general, 
though, reports of negative effects of both marijuana and hash oil were minimal, 
suggesting that the main difference in the subjective effects of marijuana and hash oil was 
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in terms of their positive effects, with marijuana producing greater positive effects than 
hash oil. 
 The present study also examined whether subjective cannabis effects differed as a 
function of frequency of hash oil use. Past research suggests that frequent cannabis users 
develop tolerance to the subjective effects of cannabis (Colizzi & Battachary, 2018). This 
increased tolerance might shift the inverted U-shaped reward-aversion curve to the right 
(Figure 2; Zernig et al., 2004). That is, at high THC concentrations, frequent hash oil 
users might experience more positive and less negative effects than infrequent hash oil 
users, who have not developed as high of a tolerance and might find such high doses of 
THC to be aversive (Figure 2). Therefore, we hypothesized that frequent hash oil users 
would experience lesser positive and lesser negative effects of marijuana than infrequent 
hash oil users. Findings revealed that frequency of hash oil use was not statistically 
significantly associated with the subjective effects of marijuana. We also hypothesized 
that frequent hash oil users would experience greater positive effects and lesser negative 
effects of hash oil than infrequent hash oil users. Findings from analyses comparing 
frequent vs. infrequent hash oil users on ratings of hash oil were generally consistent with 
hypotheses (Table 4).  
 We also hypothesized that higher tolerance among frequent hash oil users would 
result in frequent hash oil users experiencing more positive effects for hash oil than for 
marijuana and, conversely, infrequent hash oil users experiencing more positive effects 
for marijuana than for hash oil. Contrary to this hypothesis, however, both frequent and 
infrequent hash oil users rated marijuana more positively than hash oil. Moreover, we 
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hypothesized that both frequent and infrequent hash oil users would rate hash oil as 
having greater negative effects than marijuana, but we found that, at least for some 
effects, both frequent and infrequent hash oil users rated marijuana more negatively than 
hash oil. It is unclear why frequent hash oil users, who presumably have developed 
tolerance to the lower doses of THC in marijuana, would rate marijuana (which has a 
lower concentration of THC) as producing greater positive effects and in some cases 
greater negative effects (e.g., worse cognitive impairment) than hash oil (which has a 
higher concentration of THC), but we can think of several possible explanations. 
 One possible explanation is that THC alone might not underlie subjective effect 
ratings. Although THC is the main psychoactive constituent of cannabis, research has 
found that blood THC concentrations correlate only moderately with subjective drug 
effects, indicating that there are factors other than THC associated with subjective 
cannabis effects (Spindle et al., 2018). There are several hundred other chemical 
constituents (e.g., cannabinoids, terpenoids, flavonoids) that might contribute to 
subjective effects of cannabis (Ahmed et al., 2015; Aizpurua-Olaizola et al., 2016; 
ElSohly & Slade, 2005). The distribution of these chemical constituents might differ for 
marijuana and hash oil, because of the way marijuana and hash oil are prepared (Sexton, 
Shelton, Haley, and West, 2018). For example, terpenes, which produce the flavor and 
scent of cannabis, and which might also have anti-anxiety, anti-depressant, and anti-
nociceptive properties, are often lost in the hash-oil extraction process (Sexton et al., 
2018). However, this might then suggest that marijuana would be rated as producing less 
negative affect than hash oil, and this was not the case. Alternatively, various methods of 
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consuming cannabis, such as smoking or vaping, might be associated with differences in 
subjective effects (Spindle et al., 2018). There is also some research to suggest that 
smoking marijuana might be preferred because it is associated with both a tradition and a 
ritual (Murphy et al., 2015), whereas vaping either marijuana or hash oil might not 
reproduce that sense of either tradition. However, these explanations again could not 
explain the profile of findings where marijuana is rated as more extreme on only some 
effects.  
A second possible explanation is that frequent hash oil users titrate their use of 
hash oil (take smaller quantities when THC content is high) to the point that they actually 
receive lower doses of THC from hash oil than from marijuana. If frequent hash oil users 
are titrating their use of hash oil to the point that they are receiving lower doses of THC 
from hash oil than from marijuana, frequent hash oil users would rate marijuana as 
producing stronger positive and negative effects relative to hash oil. Notably, titration 
cannot fully explain the current pattern of findings as both frequent and infrequent hash 
oil users rated marijuana as producing lesser subjective effects in some outcomes (i.e., 
physiological effects and reduced consciousness) when compared with hash oil. Thus, the 
most likely answer is that there is a complex interplay between several factors, including 
constituents of marijuana and hash oil,  method of use, and quantity of cannabis used that 
might help explain why both frequent and infrequent hash oil users rated lower THC 
cannabis (i.e., marijuana) as producing greater positive and negative effects than high-
THC cannabis (i.e., hash oil).  
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The present study has several limitations. First, blood levels of THC, and factors 
that affect blood levels of THC, such as the actual THC concentration in both marijuana 
and hash oil and the amount of marijuana and hash oil typically used, were not directly 
assessed. Notably, however, research shows that, on average, hash oil contains three 
times as much THC as marijuana (ElSohly et al., 2014; Smart et al., 2017). There is also 
research to show that cannabis users receive higher doses of THC when using higher 
potency cannabis even when they attempt to titrate their dose (van der pol et al., 2014; 
Freeman et al., 2014). Nevertheless, blood tests of THC and cannabinoid content testing 
would help elucidate whether THC underlies the subjective effect ratings for cannabis 
and determine whether individuals successfully titrate their dose of THC, by taking lower 
quantities of hash oil than marijuana. Second, this is a cross-sectional study, and so we 
could not assess whether there were changes in subjective cannabis effects as frequency 
of hash oil use increased. Longitudinal studies will be needed to address this matter. 
Third, these effects might better reflect expectancies rather than in-the-moment 
subjective effects. Placebo-controlled cannabis administration studies could provide 
further insight into in-the-moment subjective effects. However, federal law in the United 
States mandates that cannabis for research purposes must come from NIDA, and 
currently NIDA does not provide cannabis with THC concentrations as high as the THC 
concentrations found in hash oil (Stith & Vigil, 2016; Vergara et al., 2017). Fourth, in 
general, our participants were frequent marijuana users, who used marijuana, on average 
five to six times per week. Therefore, findings might not generalize to novice users 
(Miller, Stogner, & Miller, 2015). Fifth, we specifically focused on butane hash oil, 
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which is the product of only one of many extraction techniques that produces hash oil. 
However, other extraction techniques are less common and produce similar products with 
similar THC concentrations (Stogner & Miller, 2015). Finally, we did not assess use of 
other cannabis preparations, such as hash and kief. These types of cannabis preparations 
are considered cannabis concentrates and have, on average, THC concentrations that are 
between the THC concentrations of marijuana and hash oil (ElSohly et al., 2016). 
 The present study contributes to the literature by providing insight into a broader 
range of positive and negative subjective effects of both marijuana and hash oil. In 
addition, this is the only extant study that has examined whether subjective cannabis 
effects differ for frequent and infrequent hash oil users. This study found that, in general, 
marijuana was rated as producing greater positive effects than hash oil. Negative effects 
for hash oil were quite minimal suggesting that, at least for experienced cannabis users, 
extreme negative subjective effects of hash oil are not likely. The present study also 
suggests that there are likely several factors, besides THC content of the cannabis, that 
relate to subjective cannabis effects. Future research on subjective effects of marijuana 
and hash oil could benefit from assessment of blood levels of THC, quantity of marijuana 
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Note: This figure is taken from Zernig et al., 2004 and illustrates the inverted U-shaped 
reward-aversion dose-effect curve in animal models whereby medium drug doses are 
more desirable than low or high drug doses. Zernig et al. (2004) suggests that this 
inverted U-shaped curve occurs because negative drug effects (labeled “rate decrease” in 
the figure) increase with increasing dose and counteract the positive effects (labeled 
“reinforcement” in the figure). This observed inverted U-shaped dose-effect curve has 
also been found in humans as well (Curran et al., 2016; Hunault et al., 2014; Sanudo-








































Figure 3. Hypothesized Association of the Subjective Effects of Marijuana Versus 
Hash Oil Among More and Less Frequent Hash Oil Users 
 
 
 Note: Test A shows the hypothesized association of positive and negative subjective 
effects of marijuana for infrequent vs. frequent hash oil users. Test B shows the hypothesized 
association of positive and negative effects of hash oil for infrequent vs. frequent hash oil users.
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Figure 4. Images of Marijuana (Panel A) and Butane Hash Oil (Panel B) 
Panel A: Marijuana. Below is marijuana, as it will be referred to in this survey. It is also 












































Panel B. Butane Hash Oil. Below is butane hash oil (BHO), as it will be referred to in this 
survey. It is also known as concentrate, wax, dab, honey oil, BHO, crumble, shatter, glass, 
honeycomb, earwax, or budder/budda. Please note that these pictures are to be used as 
























Does a circle have three sides? ‘No’ 
Does the word 'cat' have ten letters? ‘No’ 
Is the earth round? ‘Yes’ 
Is the sun hot? ‘Yes’ 
What is two plus two? ‘Four’ 
Please select 'Moderately Agree' ‘Moderately Agree’ 
Select '5' ‘5’ 
Select '6' ‘6’ 
Select ‘6’ ‘6’ 
Select '10' ’10’ 
Select ‘10’ ‘10’ 
Note: Participants answered the above questions, which were placed throughout the survey, 
to check validity of responses. To be included in the final analyses, participants had to 
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